HOME >> MEDICINE >> NEWS
Mayo Clinic finds effective treatment with minimal side effects for non-renal lupus

ROCHESTER, Minn. -- Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys. Importantly, the researchers say the drug is well tolerated and has fewer side effects than many other medications used to treat the disease.

"This would be considered a nice addition to medications we can use for these patients -- an alternative and widely applicable to many patients," says Kevin Moder, M.D., Mayo Clinic rheumatologist, who will present the findings at the American College of Rheumatology Annual Scientific Meeting in San Antonio, Texas (http://www.rheumatology.org/annual/index.asp).

Patients who have SLE, an autoimmune, inflammatory disease, may experience symptoms from fevers to joint pain to excessive fatigue to hair loss, among others. The disease also may affect major organs, and the kidneys are especially vulnerable. SLE affecting the kidneys is treated differently from non-renal SLE. Mycophenolate mofetil has been shown to be helpful in patients with lupus affecting the kidneys. The new Mayo Clinic research indicates, however, that the drug could help many more lupus patients.

Currently, there is no curative treatment for SLE. Also, many medications used to treat this disease have considerable side effects. For example, Dr. Moder explains that one currently available immunomodulatory treatment, cyclophosphamide, puts patients at risk for infertility and cancer.

"It's a significant step if the medication is effective but has fewer side effects than many medications currently used to treat lupus," says Dr. Moder.

Dr. Moder explains that while mycophenolate mofetil helps many patients, it's not 100 percent effective. He descr
'"/>


17-Oct-2004


Page: 1 2

Related medicine news :

1. Mayo Clinic discovers new pathway against pancreatic cancer
2. Mayo Clinic develops first genomic-based test to predict stroke from ruptured brain aneurysm
3. Mayo Clinic study sets threshold for valve repair surgery
4. Mayo Clinic researcher calls for improved newborn screening
5. Mayo Clinic study finds obese kidney donors face few increased risks
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Clinical breast examination offers modest benefit to breast cancer screening program
8. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
9. Clinicians report missing patient information is common
10. Mayo Clinic discovers a key to low metabolism and major factor in obesity
11. Clinical trial of Etanercept for Wegeners disease shows no benefit

Post Your Comments:
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
(Date:10/19/2014)... Having been working in the garment industry for ... needs. According to James, one of the company’s top designers, ... with high-low skirts that add beauty to them. Chiffon floor ... has unveiled its new selection of 2014 long prom dresses. ... new items are available in over 20 popular designs. The ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
(Date:10/20/2014)... Oct. 20, 2014   BioNano Genomics announced today ... ability to collect human data at 30X depth, sufficient for ... This new capability was established and demonstrated for the IrysChip ... TM System and will be rolled out to ... will be showcasing this advancement at the American Society ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
Cached News: